Published in

Springer Nature [academic journals on nature.com], British Journal of Cancer, 9(125), p. 1210-1216, 2021

DOI: 10.1038/s41416-021-01407-9

Links

Tools

Export citation

Search in Google Scholar

Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists

Journal article published in 2021 by Colin R. Lindsay, Emily C. Shaw, David A. Moore, Doris Rassl, Mariam Jamal-Hanjani, Nicola Steele, Salma Naheed, Craig Dick, Fiona Taylor, Helen Adderley, Fiona Black, Yvonne Summers, Matt Evans, Alexandra Rice, Aurelie Fabre ORCID and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

AbstractOver the past 10 years, lung cancer clinical and translational research has been characterised by exponential progress, exemplified by the introduction of molecularly targeted therapies, immunotherapy and chemo-immunotherapy combinations to stage III and IV non-small cell lung cancer. Along with squamous and small cell lung cancers, large cell neuroendocrine carcinoma (LCNEC) now represents an area of unmet need, particularly hampered by the lack of an encompassing pathological definition that can facilitate real-world and clinical trial progress. The steps we have proposed in this article represent an iterative and rational path forward towards clinical breakthroughs that can be modelled on success in other lung cancer pathologies.